NV-KALRAY
Kalray (Paris:ALKAL), a pioneer in processors for new intelligent systems, today announced the company will showcase its MPPA-3 aka Coolidge™, its third generation of unique and patented MPPA® (Massively Parallel Processor Array) processor family at CES 2020 in Las Vegas, from January 7 to 10, 2020.
COOLIDGE™ DEMONSTRATED AT CES
Just a few weeks after having received the first samples of Coolidge from manufacturing, Kalray will showcase a complete Artificial Intelligence use case running on Coolidge at CES, including a common demo with NXP, one of the leading semiconductor companies.
Coolidge samples general availability is planned for April.
COOLIDGE UNIQUELY POSITIONED FOR THE BOOMING MARKET OF INTELLIGENT SYSTEMS
Coolidge represents a 25X performance improvement(1) over second generation MPPA, with improvement of artificial intelligence capacities, increased ease of programming and higher-performance interfaces in particular for next generation of data centers.
Coolidge is targeting the booming market of intelligent systems, from next generation of data center infrastructure, 5G to next generation of cars. Coolidge is a compelling choice versus FPGA, which are expensive and difficult to program; GPU, which are tailored for mathematical algorithms; and AI processors, designed for AI only. Coolidge-based cards can be configured to deliver specialized acceleration performance in a wide set of demanding functions such as vision, signal processing, encryption, software stacks, real-time protocols, etc.
Eric Baissus, CEO of Kalray comments: “Yet another important phase for the company. Coolidge is the platform to support company's ambitions on data center markets, answering needs of growing diversity of Data Center workload acceleration and on automotive, enabling integration of multiple critical functions on the same chip while providing huge computing performance.”
DATA CENTER’S GROWING NEED FOR ACCELERATIONS AT COMPUTE, STORAGE AND NETWORKING
“2CRSi is eager to evaluate the new Coolidge processor from Kalray and excited to explore solutions leveraging Kalray’s configurable cards. The performance of this third-generation processor will enable an expansion of our offer in high-growth areas such as Artificial Intelligence or compute acceleration, while enabling more and more distributed and disaggregated data center implementations” , said Alain Wilmouth, CEO of 2CRSi.
AUTOMOTIVE AND EMBEDDED MARKETS NEED FOR INTEGRATION OF MULTIPLE CRITICAL FUNCTIONS AND HIGH COMPUTE PERFORMANCE
“We are very happy to see the strategic partnership with Kalray reach a new milestone and have Coolidge integrated into the NXP BlueBox, our development platform for automated driving, showcased at CES. We are convinced NXP and Kalray will bring multiple benefits to the development and industrialization of ADAS and AD vehicles with safe and secure solutions integrating multiple critical functions and providing very high computing performance” said Kamal Khouri, Vice President & General Manager, Advanced Driver Assistance, NXP.
Coolidge has been designed to address the challenges and constraints of the new generation of intelligent systems:
- High computing power with low energy consumption
- Open and easily programmable system
- Real-Time data processing and deterministic behavior
- Concurrent execution of many heterogeneous critical tasks in parallel on a single chip
- Advanced security and safety mechanisms suitable for the most demanding systems, defined in collaboration with Kalray’s partners in the aerospace, defense and automotive fields
For more information and to view the demonstrations, come and visit us at CES from January 7 to 10 at Las Vegas, USA: NXP’s booth #CP18, Central Plaza.
Next publication:
January 22, 2020 : H2 2019 business report
ABOUT KALRAY
Kalray (Euronext Growth Paris - FR0010722819 - ALKAL) is the pioneer in processors for new intelligent systems. A genuine technological breakthrough, “intelligent” processors are able to intelligently analyze a vast quantity of data on the fly and to make decisions and interact in real time with the outside world. These intelligent processors will be largely deployed in fast-growing sectors such as new-generation networks (intelligent data centers) and autonomous vehicles, as well as in healthcare equipment, drones and robots. Kalray’s offering spans both processors and global solutions (electronic boards and software). Created in 2008 as a spin-off of CEA (“Commissariat à l’Énergie Atomique”, the French Alternative Energies and Atomic Energy Commission), Kalray addresses a broad spectrum of customers including server manufacturers, intelligent system integrators and consumer product manufacturers such as car makers. Read more at: www.kalrayinc.com
1 25 TOPS (Tera Operations Per Second) performance for Coolidge versus 1 TOPS for previous generation Bostan
View source version on businesswire.com: https://www.businesswire.com/news/home/20200106005664/en/
Contact:
INVESTOR CONTACTS Eric BAISSUS contactinvestisseurs@kalray.eu Tel. +33 (0)4 76 18 90 71
ACTUS finance & communication Caroline LESAGE kalray@actus.fr + 33 1 53 67 36 79
MEDIA CONTACTS Loic HAMON communication@kalray.eu Tel. +33 (0)4 76 18 90 71
ACTUS finance & communication Serena BONI sboni@actus.fr Tel. +33 (0)4 72 18 04 92
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Lone Star Announces Sale of SPX FLOW to ITT Inc.5.12.2025 13:30:00 CET | Press release
Lone Star Funds (“Lone Star”) today announced the signing by an affiliate of Lone Star Fund XI, LP of a definitive agreement to sell SPX FLOW, Inc. (“SPX FLOW”), a leading provider of highly engineered equipment and process technologies for attractive end markets including industrial, health and nutrition, to ITT Inc. (NYSE: ITT) for $4.775 billion in cash and shares of common stock. Based in Charlotte, N.C., SPX FLOW focuses on process technologies delivering mixing, blending, fluid handling, separation, thermal heat transfer and other solutions integral to industrial, health and nutrition markets. The company has operations in more than 25 countries and sales in more than 140 countries. In partnership with Lone Star, SPX FLOW has focused on improving its sales execution and operating platform, while ensuring high quality and innovative product development. The management team has improved the company’s commercial organization and executed growth initiatives to build its presence in e
AmTrust Financial Services and Blackstone Credit & Insurance Close Strategic Transaction and Launch Newly Formed Multinational MGACompany Named ANV Group Holdings Ltd.5.12.2025 13:00:00 CET | Press release
Strategic Transaction Unlocks Value for AmTrust and Positions ANV Group Holdings for Accelerated GrowthFormer AmTrust President Adam Karkowsky Leading ANV Group Holdings as Chairman and CEO AmTrust Financial Services, Inc. (“AmTrust” or the “Company”), a global specialty property casualty insurer, and Blackstone Credit & Insurance (“BXCI”), today announced the closing of a strategic transaction under which AmTrust and funds managed by BXCI have partnered to spin-off certain of AmTrust’s Managing General Agencies (“MGAs”) and fee-based businesses in the U.S., United Kingdom, and Continental Europe, into ANV Group Holdings Ltd. (“ANV”), a newly formed independent company, following receipt of regulatory approvals. AmTrust and ANV have entered into a ten-year capacity agreement through which AmTrust will remain the underwriter for the existing books of business offered through the MGAs. As previously announced on September 15, 2025, the agreement includes seven AmTrust subsidiaries: ANV S
Galderma Opens up New Chapter for Sculptra® with MDR Certification and New Expanded Indication for Body5.12.2025 07:00:00 CET | Press release
Sculptra®, the first proven regenerative biostimulator, has received European Union (EU) Medical Device Regulation (MDR) certification, expanding its current clinical application for the face to include gluteal area, posterior thighs, décolletage, and upper arms1 Studies investigating the efficacy of Sculptra on areas beyond the face show patients experienced progressive improvements in skin quality (including the improvement in cellulite appearance), firmness, lift, projection, and contour Sculptra’s versatility and new indication allow practitioners to shift patient treatment goals beyond rejuvenation toward enhancement, meeting evolving patient needs The certification validates Sculptra’s safety performance, efficacy, and quality, reinforcing Galderma’s commitment to innovation and meeting evolving patient needs Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the certification of Sculptra for body indications in the European Union (EU) following its
Northern Escape Heli-Skiing Takes the Title of “World’s Best Heli-Ski-Operator” for the 4th Year Running5.12.2025 02:40:00 CET | Press release
4x World’s Best Heli-Skiing Operation near Terrace, BC Northern Escape Heli-Skiing (NEH) has been named World’s Best Heli-Ski Operator 2025 by the World Ski Awards, marking its fourth straight victory following years 2022, 2023 and 2024. This recognition places NEH amongst an elite group of ski tourism operators consistently voted best in the world by industry leaders and enthusiasts alike. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251204074550/en/ A four-year run built on reliability NEH operates in British Columbia’s Skeena Mountains, where deep northern snow and vast terrain come together with small-group heli-skiing and heli snowboarding. When helicopters can’t safely fly, NEH has cat skiing readily available as a backup — an exceedingly rare offering in this industry. The operation spans over 833,571 wild acres of alpine bowls, glaciers and old-growth tree skiing. The NEH experience Guests choose from three lodge f
IDE034, a Bispecific ADC Licensed by Biocytogen to IDEAYA, Receives FDA IND Clearance5.12.2025 01:00:00 CET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), announced that its partner IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision oncology company, has received the clearance of an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA) for the initiation of a Phase 1 clinical trial of IDE034, a potential first-in-class B7H3/PTK7 bispecific antibody-drug conjugate (ADC). IDEAYA expects to begin patient enrollment in Q1 2026, initially evaluating patients with solid tumors known to express B7H3 and PTK7, including lung, colorectal, head and neck, and ovarian/gynecological cancers. IDE034 is a bispecific B7H3/PTK7 TOP1 ADC, independently developed by Biocytogen and licensed to IDEAYA in July 2024. The IND clearance marks an important milestone for this licensed program, supporting subsequent clinical development of IDE034, while highlighting Biocytogen’s technical capabilities in bispecific ADC discovery and development. Dr. Yue
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
